|
Daily Medical Update
Cellulitis and Skin Abscess
Sunday, May 03, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Journal of Emergency Medicine (2024) - Systematic Review
Key Findings
- POCUS improved differentiation of abscess versus cellulitis across the reviewed evidence base.
- POCUS improved management decisions for SSTIs by reducing diagnostic uncertainty at the bedside.
📋 Practice Implication: Use point-of-care ultrasound early when the exam is equivocal, because the main value is deciding whether a patient needs drainage rather than antibiotics alone.
|
Infection Control and Hospital Epidemiology (2025) - Systematic Review and Meta-Analysis
Key Findings
- MRSA nares screening improved rule-in performance, with specificity of 0.949 and sensitivity of 0.474 for MRSA SSTI.
- At an MRSA prevalence of 29.1%, the negative predictive value was 0.815, supporting de-escalation when screening is negative.
📋 Practice Implication: Use a negative MRSA nares screen as one stewardship data point to step down empiric anti-MRSA therapy in appropriate cellulitis or abscess presentations.
|
JAMA Internal Medicine (2025) - Cluster Randomized Clinical Trial
Key Findings
- CPOE-guided stewardship reduced empiric extended-spectrum antibiotic days from 496.2 to 359.1 per 1000 empiric days, with a rate ratio of 0.72.
- Extended-spectrum exposure fell from 55.4% to 43.0% in the CPOE group, with no increase in ICU transfer or hospital length of stay versus routine stewardship.
📋 Practice Implication: For hospitalized noncritical SSTI, embed patient-specific MDRO risk prompts in ordering workflows to curb unnecessary antipseudomonal coverage without worsening short-term safety outcomes.
|
Journal of the American Academy of Dermatology (2025) - Phase 2 Randomized Controlled Trial
Key Findings
- Upadacitinib achieved HiSCR50 in 38.3% of patients at week 12 versus a prespecified placebo rate of 25.0% (1-sided P = .018).
- Clinical response improved across baseline Hurley stages and prior TNF inhibitor exposure, with benefit maintained through week 40.
📋 Practice Implication: In patients with recurrent abscess-forming hidradenitis suppurativa that remains uncontrolled on standard therapy, systemic JAK inhibition is becoming a plausible escalation pathway.
|
Journal of the American Academy of Dermatology (2025) - Phase 2 Randomized Controlled Trial
Key Findings
- Ruxolitinib cream reduced abscess and inflammatory nodule count more than vehicle at week 16 (least squares mean -3.61 vs -2.42; P = .0215).
- Patients using ruxolitinib cream had reduced flares versus vehicle, with no grade 3 or higher treatment-emergent adverse events reported.
📋 Practice Implication: For milder hidradenitis suppurativa with recurrent nodules or small abscesses, topical JAK therapy may offer a non-systemic option before moving to broader immunomodulation.
|
|
💡
Summary
Recent evidence for cellulitis and skin abscess centers on better bedside discrimination of abscess versus cellulitis, tighter antibiotic stewardship, and more precise treatment selection for recurrent abscess-forming hidradenitis suppurativa. Systematic review and trial data support point-of-care ultrasound for diagnostic clarification, MRSA nares screening and CPOE stewardship prompts to reduce unnecessary broad-spectrum therapy, and emerging JAK-directed options for mild-to-severe hidradenitis suppurativa.
|
|